Abstract
Epigenetic therapies may play a prominent role in the future management of solid tumors. This possibility is based on the clinical efficacy of existing drugs in treating defined hematopoietic neoplasms, paired with promising new data from preclinical and clinical studies that examined these agents in solid tumors. We suggest that current drugs may represent a targeted therapeutic approach for reprogramming solid tumor cells, a strategy that must be pursued in concert with the explosion in knowledge about the molecular underpinnings of normal and cancer epigenomes. We hypothesize that understanding targeted proteins in the context of their enzymatic and scaffolding functions and in terms of their interactions in complexes with proteins that are targets of new drugs under development defines the future of epigenetic therapies for cancer.
Original language | English (US) |
---|---|
Pages (from-to) | 56-63 |
Number of pages | 8 |
Journal | Journal of Clinical Investigation |
Volume | 124 |
Issue number | 1 |
DOIs | |
State | Published - Jan 2 2014 |
ASJC Scopus subject areas
- General Medicine